$30.59
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says
Overview
52-week range
$8.98
$41
68% of range
Avg surprise (last 3)
+2.9%
Avg reaction (last 2)
+7.0%
100% positive
Latest IV / EM
136%
EM ±31.1% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.64 | $-0.60 | -6.7% | -36.2% | +3.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.50 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.47 | $-0.53 | +11.3% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.47 | $-0.49 | +4.1% | — | +10.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.41 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.32 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.35 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.49 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.31 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.67 | -$0.47 | -42.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-42M | — | $-33M | $-31M | $-32M | — | $-29M | $-24M |
| Net income | $-39M | — | $-30M | $-28M | $-28M | — | $-24M | $-19M |
| EPS (diluted) | $-0.64 | — | $-0.50 | $-0.47 | $-0.47 | — | $-0.41 | $-0.32 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $85M | $77M | $62M | $98M | $101M | $92M | $104M | $99M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $395M | $265M | $281M | $302M | $325M | $347M | $366M | $379M |
| Total assets | $412M | $283M | $302M | $321M | $343M | $364M | $381M | $392M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $24M | $23M | $21M | $19M | $20M | $20M | $18M | $16M |
| Total equity | $388M | $259M | $281M | $302M | $324M | $343M | $362M | $376M |